Fluorouracil Injection

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

The chemical name of this product is: 5-fluoro-2,4(1H,3H)-pyrimidinedione.

This product is a colorless or almost colorless clear liquid.

This product has a wide anti-tumor spectrum and is mainly used to treat digestive tract tumors or high-dose fluorouracil to treat choriocarcinoma. It is also commonly used to treat breast cancer, ovarian cancer, lung cancer, cervical cancer, bladder cancer and skin cancer.

The dosage of fluorouracil for intravenous injection or intravenous drip varies greatly. The single-drug intravenous injection dose is generally 10-20 mg/kg per day based on body weight, used for 5-10 days, and 5-7 grams (or even 10 grams) per course of treatment. If it is intravenous drip, it is usually 300-500 mg/m2 per day based on body surface area, used for 3-5 days, and each intravenous drip time must not be less than 6-8 hours; during intravenous drip, an infusion pump can be used to continuously administer the drug for 24 hours. For primary or metastatic liver cancer, arterial catheterization is often used for injection. Intraperitoneal injection is 500-600 mg/m2 per body surface area. Once a week, 2-4 times as a course of treatment.

1. Nausea, loss of appetite or vomiting. Usually the dose is not serious. Occasionally oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea are seen. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the treatment, and returns to normal after about 3 to 4 weeks), thrombocytopenia is rare. Cough, shortness of breath or cerebellar ataxia are extremely rare. 2. Long-term use may lead to nervous system toxicity. 3. Occasionally myocardial ischemia after medication, angina pectoris and electrocardiogram changes may occur. If cardiovascular adverse reactions (arrhythmia, angina pectoris, ST segment changes) are confirmed, discontinue use.

Women are prohibited from using this drug within the first three months of pregnancy. Breastfeeding is prohibited during the use of this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not for use during the first three months of pregnancy and during lactation. Precautions for the elderly: Not yet clear.

Not yet clear.

Keep away from light and store in a sealed container.

10ml:0.25g

18 months